WO2008152086A3 - 4,5-dihydro-(1h)-pyrazole derivatives as cannabinoid cb1 receptor modulators - Google Patents

4,5-dihydro-(1h)-pyrazole derivatives as cannabinoid cb1 receptor modulators Download PDF

Info

Publication number
WO2008152086A3
WO2008152086A3 PCT/EP2008/057367 EP2008057367W WO2008152086A3 WO 2008152086 A3 WO2008152086 A3 WO 2008152086A3 EP 2008057367 W EP2008057367 W EP 2008057367W WO 2008152086 A3 WO2008152086 A3 WO 2008152086A3
Authority
WO
WIPO (PCT)
Prior art keywords
cannabinoid
dihydro
receptor modulators
compounds
methods
Prior art date
Application number
PCT/EP2008/057367
Other languages
French (fr)
Other versions
WO2008152086A2 (en
Inventor
Mahmut Yildirim
Hendrik C Wals
Vliet Bernard J Van
Josephus H M Lange
Original Assignee
Solvay Pharm Bv
Mahmut Yildirim
Hendrik C Wals
Vliet Bernard J Van
Josephus H M Lange
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv, Mahmut Yildirim, Hendrik C Wals, Vliet Bernard J Van, Josephus H M Lange filed Critical Solvay Pharm Bv
Priority to MX2009013677A priority Critical patent/MX2009013677A/en
Priority to EA201070019A priority patent/EA201070019A1/en
Priority to CN2008800204374A priority patent/CN101939300A/en
Priority to BRPI0813367A priority patent/BRPI0813367A2/en
Priority to CA002688208A priority patent/CA2688208A1/en
Priority to JP2010511635A priority patent/JP2010530367A/en
Priority to EP08774073A priority patent/EP2158184A2/en
Priority to AU2008263915A priority patent/AU2008263915A1/en
Publication of WO2008152086A2 publication Critical patent/WO2008152086A2/en
Publication of WO2008152086A3 publication Critical patent/WO2008152086A3/en
Priority to IL202299A priority patent/IL202299A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)

Abstract

This invention relates to 4,5-dihydro-(1 H)-pyrazole (pyrazoline) derivatives as cannabinoid CB1 receptor modulators, to pharmaceutical compositions containing these compounds, to methods for their syntheses, methods for preparing novel intermediates useful for their syntheses, and methods for preparing compositions. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in disorders in which CB1 receptors are involved, or that can be treated via manipulation of those receptors. The compounds have formula (I) wherein the symbols have the meanings given in the specification.
PCT/EP2008/057367 2007-06-15 2008-06-12 4,5-dihydro-(1h)-pyrazole derivatives as cannabinoid cb1 receptor modulators WO2008152086A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
MX2009013677A MX2009013677A (en) 2007-06-15 2008-06-12 4,5-dihydro-(1h)-pyrazole derivatives as cannabinoid cb1 receptor modulators.
EA201070019A EA201070019A1 (en) 2007-06-15 2008-06-12 4,5-DIHYDRO- (1H) -PYRAZOL DERIVATIVES AS MODULATORS OF CANANABINOID ST-RECEPTORS
CN2008800204374A CN101939300A (en) 2007-06-15 2008-06-12 4, 5-dihydro-(1H)-pyrazole derivatives as modulators of cannabinoid CB1receptors
BRPI0813367A BRPI0813367A2 (en) 2007-06-15 2008-06-12 compound, medicament, pharmaceutical composition, use of a compound, and process for preparing compounds.
CA002688208A CA2688208A1 (en) 2007-06-15 2008-06-12 4,5-dihydro-(1h)-pyrazole derivatives as cannabinoid cb1 receptor modulators
JP2010511635A JP2010530367A (en) 2007-06-15 2008-06-12 4,5-Dihydro- (1H) -pyrazole derivatives as cannabinoid CB1 receptor modulators
EP08774073A EP2158184A2 (en) 2007-06-15 2008-06-12 4,5-dihydro-(1h)-pyrazole derivatives as cannabinoid cb1 receptor modulators
AU2008263915A AU2008263915A1 (en) 2007-06-15 2008-06-12 4,5-dihydro-(1H)-pyrazole derivatives as cannabinoid CB1 receptor modulators
IL202299A IL202299A0 (en) 2007-06-15 2009-11-24 4,5-dihydro-(1h)-pyrazole derivatives as cannabinoid cb1 receptor modulators

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US94419407P 2007-06-15 2007-06-15
EP07110327 2007-06-15
EP07110327.9 2007-06-15
US60/944,194 2007-06-15

Publications (2)

Publication Number Publication Date
WO2008152086A2 WO2008152086A2 (en) 2008-12-18
WO2008152086A3 true WO2008152086A3 (en) 2009-05-28

Family

ID=41571026

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/057367 WO2008152086A2 (en) 2007-06-15 2008-06-12 4,5-dihydro-(1h)-pyrazole derivatives as cannabinoid cb1 receptor modulators

Country Status (8)

Country Link
EP (1) EP2158184A2 (en)
JP (1) JP2010530367A (en)
KR (1) KR20100020998A (en)
AU (1) AU2008263915A1 (en)
CA (1) CA2688208A1 (en)
EA (1) EA201070019A1 (en)
IL (1) IL202299A0 (en)
WO (1) WO2008152086A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100995882B1 (en) * 2010-06-08 2010-11-22 에이치 엘 지노믹스(주) Process for preparing intermediate of pitavastatin or its salt

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003026647A1 (en) * 2001-09-21 2003-04-03 Solvay Pharmaceuticals B.V. Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
WO2003026648A1 (en) * 2001-09-21 2003-04-03 Solvay Pharmaceuticals B.V. 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity
WO2005074920A1 (en) * 2004-01-30 2005-08-18 Solvay Pharmaceuticals B.V. 1,3,5-trisubstituted 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003026647A1 (en) * 2001-09-21 2003-04-03 Solvay Pharmaceuticals B.V. Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
WO2003026648A1 (en) * 2001-09-21 2003-04-03 Solvay Pharmaceuticals B.V. 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity
WO2005074920A1 (en) * 2004-01-30 2005-08-18 Solvay Pharmaceuticals B.V. 1,3,5-trisubstituted 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity

Also Published As

Publication number Publication date
WO2008152086A2 (en) 2008-12-18
KR20100020998A (en) 2010-02-23
IL202299A0 (en) 2010-06-30
AU2008263915A1 (en) 2008-12-18
CA2688208A1 (en) 2008-12-18
EP2158184A2 (en) 2010-03-03
EA201070019A1 (en) 2010-06-30
JP2010530367A (en) 2010-09-09

Similar Documents

Publication Publication Date Title
GEP20135907B (en) L-(piperidin-4-yl)-pyrazole derivatives as gpr 119 modulators
NO20083193L (en) 4,5-Dihydro- (1H) -pyrazole derivatives as cannabinoid CB1 receptor modulators
WO2009010455A3 (en) Pyrazole derivatives as modulators of metabotropic glutamate receptors
WO2005080343A3 (en) 3-substituted 1,5-diphenylpyrazole derivatives useful as cb1 modulators
MY149855A (en) Benzimidazole derivatives and their use for modulating the gaba? receptor complex
WO2006067428A3 (en) 1, 2-diphenyl-imidazole derivatives and their use as cb1 receptor ligands
IL176547A0 (en) 1,3,5-trisubstituted 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
UA99524C2 (en) Triazole derivatives useful for the treatment of diseases
TW200745126A (en) Bicyclic heteroaryl derivatives as cannabinoid receptor modulators
MX2008012400A (en) Azolopyrimidines as inhibitors of cannabinoid 1 activity.
HK1154587A1 (en) Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
WO2008132139A3 (en) New heterocyclic derivatives useful for the treatment of cns disorders
MY147677A (en) Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases
MY183111A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
WO2007042544A3 (en) Imidazole derivatives and their use for modulating the gabaa receptor complex
GB0519760D0 (en) Novel compounds
WO2009037244A3 (en) 5-aryl-4,5-dihydro-(1h)-pyrazoles as cannabinoid cb1 receptor agonists
TW200730500A (en) 4, 5-dihydro-(1H)-pyrazole derivatives as cannabinoid CB1 receptor modulators
MX2007012624A (en) Benzimidazole derivatives and their use for modulating the gabaa receptor complex.
MX2010003059A (en) 5-aryl-4,5-dihydro-(1h)-pyrazoles as cannabinoid cb1 receptor agonists.
WO2008152086A3 (en) 4,5-dihydro-(1h)-pyrazole derivatives as cannabinoid cb1 receptor modulators
WO2009117283A3 (en) Quinolizidinone m1 receptor positive allosteric modulators
MX2009013677A (en) 4,5-dihydro-(1h)-pyrazole derivatives as cannabinoid cb1 receptor modulators.
UA92736C2 (en) 1h-imidazole derivatives as cannabinoid cb2 receptor modulators
NO20090539L (en) Azaindole derivatives with a combination of partial nicotinic acetylcholine receptor agonism and dopamine reuptake inhibition

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880020437.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08774073

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 12009502216

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2688208

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010511635

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2008774073

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009121823

Country of ref document: EG

Ref document number: 7311/CHENP/2009

Country of ref document: IN

Ref document number: MX/A/2009/013677

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: DZP2010000013

Country of ref document: DZ

ENP Entry into the national phase

Ref document number: 20107000892

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201070019

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2008263915

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PI 20095314

Country of ref document: MY

ENP Entry into the national phase

Ref document number: 2008263915

Country of ref document: AU

Date of ref document: 20080612

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0813367

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20091215